Stock MOREPENLAB MOREPEN LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Morepen Laboratories Limited

Equities

MOREPENLAB

INE083A01026

Delayed Bombay S.E.
Other stock markets
 02:10:55 2024-07-16 am EDT 		5-day change 1st Jan Change
56.52 INR +1.22% Intraday chart for Morepen Laboratories Limited -2.77% +16.46%
May. 21 Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Mar. 30 Morepen Laboratories Limited Announces Resignation of Lalit Kumar Baregama, Chief Growth Officer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Morepen Laboratories : Change in Senior Management Personnel - Mr. Rajesh Kumar Singh
PU
Morepen Laboratories : Investors Presentation Q4' FY 2023 2024
PU
Morepen Laboratories : Change in the date of appointment of Mr. Nishant Jayesh Doshi, V P - Corp. Fin. & Investor Relations ('SMP') Change in Senior Management Personnel - Mr. Rajesh Kumar Singh
PU
Morepen Laboratories : Dr. Morepen Partners with OptiBiotix to Deliver Safe, ScienceBacked Weight Management Solution to India
PU
Morepen Laboratories : Investors presentation - Q1' FY 2023-24
PU
Morepen Laboratories : Transcript of EGM dated March 05, 2022  Audited Financial results for the quarter and financial year ended March 31, 2022  Unaudited financial results for the quarter and nine months ended December 31, 2021  Unaudited Financial results for the quarter and half year ended September 30, 2021  Unaudited Financial results for the quarter ended June 30, 2021
PU
Morepen Laboratories : Investor Presentation Q1' FY 2022-23
PU
Morepen Laboratories : Unaudited Financial results for the quarter ended June 30, 2022
PU
Morepen Laboratories : Conversion
PU
Morepen Laboratories : Extra Ordinary Meeting
PU
Morepen Laboratories : Investor Presentation Q3' FY 2021-22
PU
Morepen Laboratories : Labs Q3 Revenue up by 29% with 14% jump in Profit before Tax (PBT), 43% increase in API Export
PU
Morepen Laboratories : gets USFDA Approval for Fexofinadine (Allegra) Expected to start export in Q4’FY22
PU
Morepen records 70 percent increase in Profit before tax in Q2 Consolidated Revenue grows by 17%
PU
Investor Presentation Q2'FY2021-22
PU
Morepen Laboratories : Press Release 29 September 2021
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MOREPENLAB Stock
  4. News Morepen Laboratories Limited
  5. Press Releases